Latest Big-Newsletter reports on the ABCSG 63 / ERIKA Trial
17.04.2024
ABCSG 63 / ERIKA (Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer) trial to start study recruitment in Q2 2024!
ABCSG 63 is an innovative, investigator-initiated trial in its final set-up phase, to be conducted in Austria and Germany under the academic sponsorship of ABCSG, and at approximately 18 trial sites with the recruitment target of 120 patients.
read more
Austrian Breast & Colorectal Cancer Study Group
